Blockage of arteries that supply arms or legs may result in necrosis and gangrene
Temporary or permanent decrease or loss of other organ functions
In septic embolism, there can be infection of the affected tissue or even septic shock, potentially leading to gangrene and sepsis

Epidemiology
In the United States, approximately 550,000 people die each year from heart-related arterial embolism and thrombosis. Approximately 250,000 of these individuals are female, and approximately 100,000 of all these deaths are considered premature, that is, prior to the age of average life expectancy. References


== External links ==
The ointment formulation (Taclonex) was approved in 2006, by the US Food and Drug Administration (FDA) for the treatment of psoriasis vulgaris in adults 18 years and older. The topical suspension formulation (Taclonex) was approved in 2008, by the FDA for the treatment of plaque psoriasis of the scalp and body in adults 18 years and older. In 2014, the FDA also approved the topical suspension formulation for the treatment of plaque psoriasis of the scalp in adolescents aged 12 to 17 years. The foam formulation (Enstilar) was approved in October 2015, by the U.S. Food and Drug Administration. The ointment and topical suspension formulation (Daivobet) were also approved in 2010 by the European Medicines Agency for the treatment of plaque psoriasis where it is possible to use a topical medication (ointment), and for the treatment of scalp psoriasis or mild to moderate plaque psoriasis on the body (topical suspension). References
Further reading
External links
"Betamethasone dipropionate mixture with calcipotriene". Drug Information Portal. U.S. National Library of Medicine.